Earlier this week PhRMA submitted comments to the National Institute of Standards and Technology (NIST) regarding the proposed rulemaking on implementing regulations of the Bayh-Dole Act. Passed in 1980, the Bayh-Dole Act was a landmark piece of bipartisan legislation that established a uniform framework across the federal government to encourage technology transfer between universities and the private sector that has facilitated timely and efficient commercialization of early-stage research. Since its passage, it has fueled unprecedented innovation across the United States.